NCT03263624 is a Phase 4 clinical trial of fractional carbon dioxide laser in Nail Psoriasis, sponsored by Assiut University.

Who is sponsoring NCT03263624?

NCT03263624 is sponsored by Assiut University.

What drugs are being tested in NCT03263624?

Interventions in NCT03263624: fractional carbon dioxide laser, Tazarotene Cream 0.1%.

What condition does NCT03263624 study?

NCT03263624 studies Nail Psoriasis.

Is NCT03263624 still recruiting?

NCT03263624 is currently status unknown. Last updated 28 August 2017.

Last reviewed 2017-08-28 · How we verify

NCT03263624

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic Nail Disease

Status unknown Phase 4 Last updated 28 August 2017

What this trial tests

Phase 4 trial testing fractional carbon dioxide laser in Nail Psoriasis in 30 participants. Status unknown.

Timeline

1 October 2017

Primary endpoint
1 October 2018

1 November 2018

Quick facts

Lead sponsor	Assiut University
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 October 2017
Primary completion	1 October 2018
Estimated completion	1 November 2018

Drugs / interventions tested

fractional carbon dioxide laser
Tazarotene Cream 0.1%

Conditions studied

Nail Psoriasis — all drugs for Nail Psoriasis →

Sponsor

Assiut University

Who can join

Eligibility, any sex, with Nail Psoriasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Nail psoriasis has a high incidence amongst patients with psoriasis.It is estimated to affect 80% of psoriatic patients at some time during their lives and has a significant adverse influence on their quality of life. Treatment of nail psoriasis is disappointing, as it is refractory to treatment, with conventional therapies often having little effect.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of fractional carbon dioxide laser

Trials testing the same drug.

NCT05923996 — Fractional Co2 Laser Versus Microbotox Injection in the Treatment of Wide Facial Pores: A Split Face Comparative Study · Phase 1 · unknown
NCT03535051 — Efficiency of Fractional-Laser Resurfacing Followed by Topical Tacrolimus 0.03% Cream vs Tacrolimus Alone in Vitiligo · NA · completed

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03263624 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 28 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03263624.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing